Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

\- This will a be an open label, multicentre, randomized, controlled study in patients with unresectable pancreatic cancer, locally advanced or metastatic, with significant weight loss, and the tumour located in the head of the pancreas associated with dilated main pancreatic duct. Pancreatic Exocrine Replacement Therapy (PERT) in these patients will be given on top of other required therapies (best standard of care, BSC), including oncologic therapies, diabetes mellitus therapies and acid suppressants and nutritional support as appropriate. The duration of the study will be up to six months.

Trial Details

NCT ID
NCT06099119
Phase
PHASE4
Sponsor
Hospital Clinico Universitario de Santiago
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • creon 35.000 Ph.U (R)
  • Best Standarard of Care
Locations (sample)
  • Milan, Milan, Italy|45.46427,9.18951
  • Santiago de Compostela, A Coruna, Spain|42.88052,-8.54569
  • Pamplona, Navarre, Spain|42.81687,-1.64323
  • Stockholm, Stockholm County, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Pathologically confirmed unresectable, locally advanced or metastatic, pancreatic cancer.
  • Tumour located in the head of the pancreas.
  • Dilated main pancreatic duct confirmed by imaging methods (CT scan, MRI and/or EUS).
  • Significant weight loss (≥5% of the usual body weight) at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →